Last reviewed · How we verify
Dengue Tetravalent Vaccine, Live
At a glance
| Generic name | Dengue Tetravalent Vaccine, Live |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge (PHASE1)
- Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases (PHASE4)
- Dengvaxia US Pregnancy Registry
- A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan (PHASE2, PHASE3)
- A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India (PHASE3)
- Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002) (PHASE2)
- A Study in Children and Adolescents on the Effectiveness of Takeda's Licensed Dengue Vaccine TDV Against Hospitalization Due to Dengue Disease
- A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dengue Tetravalent Vaccine, Live CI brief — competitive landscape report
- Dengue Tetravalent Vaccine, Live updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI